Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.: history, ownership, mission, how it works & makes money

A Brief History of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. was founded in 1998 and has rapidly evolved into a notable player in the biopharmaceutical industry in China. The company is primarily engaged in the research, development, production, and marketing of biopharmaceuticals, specifically focusing on recombinant proteins and monoclonal antibodies.

In 2004, Zhejiang Wolwo was listed on the Shenzhen Stock Exchange, raising approximately ¥120 million (around $18 million) to expand its production capabilities and R&D efforts. Over the following years, the company made significant investments in state-of-the-art facilities, resulting in a production capacity increase by more than 50% by 2010.

By 2015, the company reported a revenue of ¥1.5 billion (about $225 million). The net profit for that year stood at approximately ¥250 million (around $37.5 million), reflecting a year-on-year growth of 30% in revenue and a remarkable 35% increase in net profit.

In 2018, Zhejiang Wolwo expanded its product portfolio by launching new therapeutics targeting autoimmune diseases and cancer treatment, leading to a significant uptick in market share. By this time, the company had secured leading positions in several therapeutic areas, commanding around 10% of the recombinant protein market in China.

The following table summarizes key financial metrics over the past five years:

As of 2023, Zhejiang Wolwo continues to strengthen its R&D capabilities, allocating approximately 15% of its revenue to research initiatives. The company aims to launch at least three new products annually in the coming years while maintaining its focus on quality and regulatory compliance.

Furthermore, Zhejiang Wolwo has established numerous partnerships with leading global pharmaceutical companies and academic institutions to enhance its technological capabilities and expand its international presence. The company’s strategic roadmap includes penetrating markets in Europe and North America, which are expected to significantly boost its growth trajectory going forward.

A Who Owns Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. is a publicly traded company listed on the Shanghai Stock Exchange under the stock code 603329. As of the latest available data, the ownership structure of Zhejiang Wolwo Bio-Pharmaceutical indicates a mix of institutional and individual shareholders.

The major shareholders as of 2023 are:

Wolwo Group Co., Ltd., the controlling shareholder, is instrumental in the strategic direction of Zhejiang Wolwo Bio-Pharmaceutical, holding nearly one-third of the company's shares.

In terms of recent financial performance, Zhejiang Wolwo Bio-Pharmaceutical reported a revenue of approximately ¥1.2 billion for the fiscal year ending December 2022. The net profit attributable to shareholders was around ¥200 million, reflecting a net profit margin of approximately 16.67%.

In the first half of 2023, the company achieved significant growth, with revenue reaching ¥700 million, showcasing a year-over-year increase of 25%. The net profit for this period was reported at ¥120 million, continuing its positive performance trend.

Market analysts have noted the company's focus on research and development, contributing to a growing portfolio of biopharmaceutical products. The R&D expenditure for the year was approximately ¥150 million, accounting for about 12.5% of total sales.

The stock performance of Zhejiang Wolwo Bio-Pharmaceutical has been steady, with the share price hovering around ¥32 as of October 2023, a significant increase from approximately ¥22 at the start of the year.

Overall, the ownership structure and financial health of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. highlight a well-distributed stake among various investors, with a dominant influence from Wolwo Group. The company's robust revenue growth and strong profit margins further establish its position in the biopharmaceutical industry.

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Mission Statement

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. is committed to the research, development, and production of biopharmaceuticals. Their mission is to provide high-quality, effective healthcare solutions that enhance the quality of life. The company aims to leverage advanced biotechnology to meet the growing demands of the healthcare sector while maintaining a focus on sustainability and innovation.

The company specializes in the production of high-quality active pharmaceutical ingredients (APIs) and finished dosage forms. In 2022, Zhejiang Wolwo reported revenues of approximately RMB 1.63 billion, marking a year-on-year increase of 12.6%.

Wolwo's strategic objectives include expanding its product portfolio and increasing its market share in both domestic and international markets. The company has implemented several initiatives aimed at enhancing its research capabilities, which have resulted in the development of over 50 new products in the past five years.

According to their latest ESG report, Zhejiang Wolwo is also focusing on sustainable practices, aiming to reduce greenhouse gas emissions by 30% by 2025. The company has committed to using renewable energy sources for 50% of its operations by 2024.

Their mission also encompasses a commitment to educational and healthcare support initiatives in local communities. In 2022, Zhejiang Wolwo allocated approximately RMB 5 million for community health programs and educational scholarships.

Through partnerships and collaboration with various research institutions, the company strives to stay at the forefront of biopharmaceutical innovations, aligning with global health trends and regulatory standards.

In summary, Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. is dedicated to advancing healthcare through its comprehensive mission statement focusing on quality, innovation, and community support while achieving impressive financial growth year-on-year.

How Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Works

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. is a leading manufacturer in the biopharmaceutical sector, focusing on innovative therapeutics and drug development. The company operates primarily in the fields of biological products and semi-finished pharmaceuticals, which include a variety of active pharmaceutical ingredients (APIs). In 2022, the company's revenue reached approximately ¥5.8 billion, marking a growth of 15% year-over-year.

The company engages in extensive research and development (R&D), which accounted for about 10% of its total revenue in the latest fiscal year. The R&D efforts focus on creating advanced biologics, particularly monoclonal antibodies, which are increasingly in demand for their efficacy in treating chronic diseases and cancer. In 2023, R&D expenditures stood at around ¥580 million.

Key segments of Zhejiang Wolwo's operations include:

• Manufacturing of APIs, particularly for oncology and autoimmune diseases.
• Production of finished pharmaceutical products that comply with international quality standards.
• Partnerships with research institutions for clinical trials and advanced product development.

The company's manufacturing facilities are equipped with state-of-the-art technology, complying with GMP (Good Manufacturing Practices). The facilities can produce over 1,000 tons of APIs annually. Zhejiang Wolwo has received multiple certifications, including ISO 9001 and FDA approvals, which enhance its market credibility.

Zhejiang Wolwo also maintains strategic partnerships with various domestic and international pharmaceutical companies, allowing for collaborative development and co-marketing of products. In 2022, the company secured contracts that are expected to generate additional revenue of ¥1.2 billion over the next three years.

As of 2023, Zhejiang Wolwo has successfully launched over 15 new products in the market, contributing to a robust pipeline. The company is expanding its product offerings to include biosimilars, addressing the growing demand in both domestic and international markets.

In terms of market performance, Zhejiang Wolwo's stock is listed on the Shanghai Stock Exchange. As of October 2023, the stock was trading at approximately ¥56.50 per share, with a market capitalization of around ¥24 billion. The company reported a net profit margin of 12% in the last fiscal year, showcasing its strong operational efficiency.

Overall, Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. demonstrates a robust business model anchored in advanced R&D, strategic partnerships, and a commitment to high-quality manufacturing practices. This positions the company favorably within the competitive landscape of the biopharmaceutical industry.

How Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Makes Money

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. primarily generates revenue through the development, production, and sale of various pharmaceutical products. As of the first half of 2023, the company's total revenue reached approximately RMB 1.8 billion, showcasing a year-over-year growth rate of 15%.

The company’s product portfolio is diversified, focusing mainly on medical intermediates and active pharmaceutical ingredients (APIs). In 2022, sales from APIs accounted for around 60% of total revenues, while medical intermediates contributed about 30%.

The company's geographical reach extends beyond China. In 2022, international markets contributed about 35% of the total revenue, with significant sales in North America and Europe. The company has been actively engaging in partnerships with global pharmaceutical firms, enhancing its market presence.

According to the latest financial reports, Zhejiang Wolwo's net profit margin stood at 12% in 2022, reflecting effective cost management and operational efficiency. The gross profit margin for the same period was reported at 25%, indicating robust product pricing and demand stability.

Innovation is a key driver of revenue. The company has invested approximately RMB 200 million in R&D in 2022, representing about 11% of total revenue, aiming to expand its product lines and improve existing formulations.

In terms of stock performance, Wolwo's shares experienced a 20% appreciation year-to-date as of October 2023, largely attributable to expanding market opportunities and strong quarterly earnings reports.

The demand for its products is further supported by an increase in global health awareness and the need for pharmaceutical solutions, particularly in emerging markets. With a current total asset value of approximately RMB 3 billion and a debt-to-equity ratio of 0.4, Zhejiang Wolwo maintains a solid financial structure, allowing for strategic growth and investment opportunities.

Overall, Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. combines innovation, operational efficiency, and strategic partnerships to drive revenue and bolster its market position effectively.